Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 1 · 33.3%High 0 · 0%

Hyperimmune immunoglobulin from human plasma vs saline placebo

Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19

Hyperimmune immunoglobulin from human plasma probably leads to higher adverse events at grades 3 to 4 up to 28 days compared with saline placebo (moderate certainty).

1 finding from 1 review

Hyperimmune immunoglobulin for people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 4.09 [1.39, 12.01]
Studies not reported
Moderate

Hyperimmune immunoglobulin from human plasma vs saline placebo

Adverse events: all grades · individuals with moderate or severe COVID‐19

Hyperimmune immunoglobulin from human plasma showed no clear difference in adverse events of any grade up to 28 days (data only available for… compared with saline placebo (low certainty).

1 finding from 1 review

Hyperimmune immunoglobulin for people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.98 [0.81, 1.18]
Studies not reported
Low

Hyperimmune immunoglobulin from human plasma vs saline placebo

Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28) · individuals with moderate or severe COVID‐19

Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).

1 finding from 1 review

Hyperimmune immunoglobulin for people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.72 [0.45, 1.14]
Studies not reported
Low